Cytec Industries (CYT) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- S&P 500, Nasdaq futures slip as investors eye SK Hynix listing, Middle East risks
- Oil heads for weekly gain as Middle East supply risks persist
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
March 16, 2022 4:01 PM EDT- Continue to enroll in monotherapy and combination studies with CYT-0851 with potential for interim safety and efficacy data in second half 2022
- Progress achieved in key clinical milestones described in the 2021 IPO: Advanced CYT-0851 monotherapy to Phase 2 and initiated Phase 1 combination therapy study
- Projected cash runway into 2024 to support planned R&D and clinical studies
- Conference call and webcast scheduled for 4:30 p.m. ET on March 16, 2022
LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company... More
